Prophylactic administration of IgY antibodies targeting P. aeruginosa significantly reduced the bacterial burden by 2-log 24 h postinfection
compared to controls and was accompanied by significantly reduced clinical symptom scores and successive inflammatory cytokine
profile indicative of diminished lung inflammation